Abstract
Background: Crimean‐Congo hemorrhagic fever (CCHF) is an acute illness affecting multiple organ systems and characterized by ecchymosis, visceral bleeding, and hepatic dysfunction. In this study, we aimed to investigate the profile of coagulopathy markers (platelet count, activated partial tromboplastin time (aPTT), prothrombin time (PT), international normalized ratio (INR), fibrinogen, protein C, protein S, antithrombin III, activated protein C resistance (APCR), and D‐dimer) and their clinical significance in 83 CCHF‐infected patients. Subjects and methods: We studied 83 CCHF patients who were admitted to Ankara Numune Education and Research Hospital during the spring and summer of2007. We compared the coagulopathy markers of fatal CCHF patients (n=9) with nonfatal cases (n=74). Results: Platelet count, PT, aPTT, INR, and fibrinogen were prognostic factors associated with mortality for CCHF. Especially, platelet count<20×109 cells/l and aPTT>60 sec were important. Protein C, protein S, APCR, and antithrombin III levels were not associated with mortality. Conclusion: Laboratory tests including classical parameters (platelet count, PT, aPTT, INR, and fibrinogen) of coagulopathy seem to be enough for the followup of CCHF. Protein S, protein C, APCR, and D‐dimer levels were not associated with mortality. J. Clin. Lab. Anal. 24:163–166, 2010. © 2010 Wiley‐Liss, Inc.
Keywords: Crimean‐Congo hemorrhagic fever, protein C, protein S, antithrombin III, activated protein C resistance
REFERENCES
- 1. Whitehouse CA. Crimean‐Congo hemorrhagic fever. Antiviral Res 2004;64:145–160. [DOI] [PubMed] [Google Scholar]
- 2. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S. The clinical pathology of Crimean‐Congo hemorrhagic fever. Rev Infect Dis 1989;11:794–800. [DOI] [PubMed] [Google Scholar]
- 3. Vorou R, Pierroutsakos IN, Maltezou HC. Crimean‐Congo hemorrhagic fever. Curr Oppin Infect Dis 2007;20:495–500. [DOI] [PubMed] [Google Scholar]
- 4. Centers for Disease Control and Prevention (CDC) . Update: management of patients with suspected viral hemorrhagic fever‐United States. MMWR Morb Mortal Wkly Rep 1995;44:475–479. [PubMed] [Google Scholar]
- 5. Cevik MA, Erbay A, Bodur H, et al. Clinical and laboratory features of Crimean‐Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis 2008;12:374–379. [DOI] [PubMed] [Google Scholar]
- 6. Cevik MA, Erbay A, Bodur H, et al. Viral load as a predictor of outcome in Crimean‐Congo hemorrhagic fever. Clin Infect Dis 2007;45:96–100. [DOI] [PubMed] [Google Scholar]
- 7. Onguru P, Akgul EO, Akinci E, et al. High serum levels of neopterin in patients with Crimean‐Congo hemorrhagic fever and its relation with mortality. J Infect 2008;56:366–370. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Schnittler HJ, Feldmann H. Viral hemorrhagic fever—a vascular disease?. Thromb Haemost 2003;89:967–972. [PubMed] [Google Scholar]
- 9. van Gorp EC, Suharti C, ten Cate H, et al. Infectious diseases and coagulation disorders. J Infect Dis 1999;180:176–186. [DOI] [PubMed] [Google Scholar]
- 10. Avila‐Aguero ML, Avila‐Aguero CR, Um SL, Soriano‐Fallas A, Cañas‐Coto A, Yan SB. Systemic host inflammatory and coagulation response in the Dengue virus primo‐infection. Cytokine 2004;27:173–179. [DOI] [PubMed] [Google Scholar]
- 11. Ergonul O, Tuncbilek S, Baykam N, Celikbas A, Dokuzoguz B. Evaluation of serum levels of interleukin (IL)‐6, IL‐10, and tumor necrosis factor‐alpha in patients with Crimean‐Congo hemorrhagic fever. J Infect Dis 2006;193:941–944. [DOI] [PubMed] [Google Scholar]
- 12. Griffin JH, Fernández JA, Gale AJ, Mosnier LO. Activated protein C. J Thromb Haemost 2007;5:73–80. [DOI] [PubMed] [Google Scholar]
- 13. van't Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin‐III, and heparin cofactor‐II. J Biol Chem 1997;272:4367–4377. [DOI] [PubMed] [Google Scholar]
- 14. Yapar M, Aydogan H, Pahsa A, et al. Rapid and quantitative detection of Crimean‐Congo hemorrhagic fever virus by one‐step real‐time reverse‐transcriptase PCR. Jpn J Infect Dis 2005;58:358–362. [PubMed] [Google Scholar]
- 15. Nguyen TH, Lei HY, Nguyen TL, et al. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis 2004;189:221–232. [DOI] [PubMed] [Google Scholar]
- 16. Hensley LE, Stevens EL, Yan SB, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007;196:390–399. [DOI] [PubMed] [Google Scholar]
- 17. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327–1330. [PubMed] [Google Scholar]